| Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors. | Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors.
Hashimoto K, Nishimura S, Shinyashiki Y, Ito T, Kakinoki R, Akagi M., Free PMC Article | 06/7/2023 |
| Clinicopathological assessment of cancer/testis antigens NYESO1 and MAGEA4 in osteosarcoma. | Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.
Hashimoto K, Nishimura S, Ito T, Oka N, Kakinoki R, Akagi M., Free PMC Article | 07/2/2022 |
| MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. | MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Ishihara M, Kageyama S, Miyahara Y, Ishikawa T, Ueda S, Soga N, Naota H, Mukai K, Harada N, Ikeda H, Shiku H., Free PMC Article | 02/2/2021 |
| T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. | T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH, McMurran C, Lloyd A, Hock M, Hibbert L, Raman MCC, Hayes C, Lupardus P, Cole DK, Harper S., Free PMC Article | 01/23/2021 |
| Because of the significant correlation of MAGEA4 and indices of poor prognosis, the role of this CTA may be confirmed in Esophageal squamous cell carcinoma (ESCC) aggressiveness and metastasis. Therefore, MAGEA4 may be a promising therapeutic candidate for suppressing ESCC aggressiveness | Investigation of melanoma-associated antigen A4 cancer/testis antigen clinical relevance in esophageal squamous cell carcinoma.
Sani SA, Forghanifard MM, Sharifi N, Bidokhti MH, Bagherpoor AJ, Abbaszadegan MR. | 11/3/2018 |
| Study shows that whereas MAGEA4 expression by itself may be indicative of a poor prognosis in primary lung cancer, its prognostic value depends entirely on its subcellular localization and on the p53 status. The accumulation of nuclear MAGEA4 expression without p53 expression is significantly associated with poor survival, implying that MAGEA4 inhibits apoptosis and increases tumorigenesis. | Prognostic value of MAGEA4 in primary lung cancer depends on subcellular localization and p53 status.
Fujiwara-Kuroda A, Kato T, Abiko T, Tsuchikawa T, Kyogoku N, Ichinokawa M, Tanaka K, Noji T, Hida Y, Kaga K, Matsui Y, Ikeda H, Kageyama S, Shiku H, Hirano S. | 10/27/2018 |
| MAGE-A4 depletion from MAGE-A4-expressing cancer cells destabilizes RAD18. | A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis.
Gao Y, Mutter-Rottmayer E, Greenwalt AM, Goldfarb D, Yan F, Yang Y, Martinez-Chacin RC, Pearce KH, Tateishi S, Major MB, Vaziri C., Free PMC Article | 08/25/2018 |
| Our results support...the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma | MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
Iura K, Kohashi K, Ishii T, Maekawa A, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Matsumoto Y, Iwamoto Y, Oda Y. | 03/24/2018 |
| some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. | Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer.
Werner S, Chen H, Butt J, Michel A, Knebel P, Holleczek B, Zörnig I, Eichmüller SB, Jäger D, Pawlita M, Waterboer T, Brenner H., Free PMC Article | 02/3/2018 |
| Anti-MAGEA4 exhibited the highest sensitivity for detecting early stage colorectal cancer (CRC) and advanced adenoma. | Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.
Chen H, Werner S, Butt J, Zörnig I, Knebel P, Michel A, Eichmüller SB, Jäger D, Waterboer T, Pawlita M, Brenner H., Free PMC Article | 12/2/2017 |
| High MAGE-A4 expression is associated with Lung Cancer. | Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
Myšíková D, Adkins I, Hradilová N, Palata O, Šimonek J, Pozniak J, Kolařík J, Skallová-Fialová A, Špíšek R, Lischke R. | 11/25/2017 |
| Results found concomitant overexpression of MAGEA4 and TWIST1 in esophageal squamous cell carcinoma (ESCC). Also, it showed a correlation between MAGEA4 and TWIST1 expression, which was found as indirect binding of TWIST1 to the E-boxes in the MAGEA4 promoter revealing transcriptional upregulation of MAGEA4 by TWIST1. | TWIST1 upregulates the MAGEA4 oncogene.
Forghanifard MM, Rad A, Farshchian M, Khaleghizadeh M, Gholamin M, Moghbeli M, Abbaszadegan MR. | 09/9/2017 |
| Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. | Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y, Oda Y. | 09/2/2017 |
| Data show that overall survival (OS) was significantly lower for patients expressing pan-MAGE or MAGE-A1/A3/A4 in both independent cohorts. | MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.
Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S., Free PMC Article | 08/19/2017 |
| the crystal structures of MAGE-A3 and MAGE-A4 | Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.
Newman JA, Cooper CD, Roos AK, Aitkenhead H, Oppermann UC, Cho HJ, Osman R, Gileadi O., Free PMC Article | 07/30/2016 |
| CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. | Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C, Xu Y, Li X, Ren S, Zhao C, Hou L, Ye Z, Zhou C., Free PMC Article | 05/28/2016 |
| HLA class I loss in smokers or patients with the MAGE-A4 gene was a prognostic factors in non-small cell lung cancer . | Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.
Baba T, Shiota H, Kuroda K, Shigematsu Y, Ichiki Y, Uramoto H, Hanagiri T, Tanaka F. | 08/23/2014 |
| Expression of MAGE-A4 may make immunotherapeutic intervention possible in selected patients with thyroid cancer. | Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S., Free PMC Article | 01/25/2014 |
| Detection of MAGE-4 transcripts in blood may help to predict the prognosis and monitoring of the response of HCV-infected hepatocellular carcinoma patients to therapy | MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.
Hussein YM, Morad FE, Gameel MA, Emam WA, El Sawy WH, El Tarhouny SA, Bayomy ES, Raafat N. | 07/20/2013 |
| Mage-A4 expression and serum identification is and potential therapeutic target in estrogen receptor negative breast cancer. | Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE, Moreira JM., Free PMC Article | 07/13/2013 |
| MAGEA4 promotes growth by preventing cell cycle arrest and by inhibiting apoptosis mediated by the p53 transcriptional targets. | MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis.
Bhan S, Chuang A, Negi SS, Glazer CA, Califano JA. | 05/11/2013 |
| High MAGE-4 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. | MAGE-3 and MAGE-4 genes as possible markers for early detection of metastases in hepatitis C virus Egyptian patients complicated by hepatocellular carcinoma.
Hussein YM, Ghareib AF, Mohamed RH, Radwan MI, Elsawy WH. | 09/22/2012 |
| Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells. | MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases.
Shin KC, Lee KH, Lee CH, Shin IH, Suh HS, Jeon CH., Free PMC Article | 06/2/2012 |
| Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. | Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S. | 05/26/2012 |
| MAGE-A4 is identified as a specific biomarker of esophageal squamous cell carcinoma with a possible oncogenic role contributing to tumor progression. | Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: identification of specific tumor marker and potential targets for immunotherapy.
Forghanifard MM, Gholamin M, Farshchian M, Moaven O, Memar B, Forghani MN, Dadkhah E, Naseh H, Moghbeli M, Raeisossadati R, Abbaszadegan MR. | 02/11/2012 |